Last updated: March 13, 2026
What is the case about?
Pfizer Inc. filed a patent infringement lawsuit against Synthon Pharmaceuticals, accusing Synthon of infringing U.S. Patent No. 10,592,107 ("the '107 patent") related to a method of synthesizing a therapeutic compound. The lawsuit, filed in the District of Delaware in January 2021, aims to prevent Synthon from manufacturing or selling generic versions of Pfizer's branded drug.
What are the key patent claims involved?
The '107 patent claims a specific process of synthesizing a drug compound used in Pfizer's medications. The patent claims focus on the use of particular reagents, reaction conditions, and intermediate compounds to improve yield and purity.
| Patent Number |
Filing Date |
Expiry Date |
Claims |
Patent Status |
| 10,592,107 |
July 17, 2018 |
July 17, 2038 |
18 claims covering a synthetic process |
Issued, enforceable as of 2020 |
Procedural history
- January 2021: Pfizer files complaint alleging patent infringement.
- April 2021: Synthon files a motion to dismiss or for judgment on the pleadings, challenging the validity of the patent under Sections 101 and 103.
- June 2021: The court denies Synthon's motion, permitting the case to proceed.
- December 2021: Discovery phase begins; Pfizer seeks to establish the validity and infringement, while Synthon seeks to show the patent is invalid.
- October 2022: The parties engage in settlement negotiations, which later fail to produce a resolution.
Legal issues at stake
Patent validity
Pfizer maintains its patent is valid due to inventive steps in the process, emphasizing its novelty and non-obviousness over prior art.
Patent infringement
Pfizer claims Synthon's process infringes the '107 patent claims, as Synthon's process uses identical or equivalent steps.
Defenses raised by Synthon
- Patent invalidity under Section 103 (obviousness).
- Patent ineligibility under Section 101 concerning patentable subject matter.
- Non-infringement, asserting differences in process steps.
Evidence and key arguments
- Pfizer submitted expert reports demonstrating the process's novelty, compliance with patentability criteria, and potential advantages.
- Synthon argued that prior art references, including earlier synthesis methods, render the patent obvious.
- Synthon challenged the patent's claims under 101 for failure to meet patentable subject matter requirements by claiming the process is an abstract idea or natural law.
Recent developments
- May 2023: The court issued an order denying Synthon’s motion for summary judgment, allowing the case to proceed to trial.
- October 2023: Pre-trial procedures are underway, including expert depositions on validity and infringement.
- The trial is scheduled for late 2024 and is expected to focus on validity defenses and infringement claims.
Litigation implications
The case underscores the importance of detailed patent drafting, especially regarding process claims for complex chemical syntheses. A successful defense by Synthon on validity could open the door for generic entry but depends on the court's assessment of prior art and patentability criteria. Pfizer’s ability to prove infringement will hinge on technical correspondences between the accused process and the patent claims.
Strategic considerations
- Pfizer aims to enforce patent rights to maintain market exclusivity.
- Synthon seeks to invalidate the patent to accelerate generic drug entry.
- The outcome may influence patent prosecution standards for chemical processes.
- The case could set a precedent for litigation involving process patents in biologics and small molecule drugs.
Key takeaways
- Pfizer’s '107 patent covers a specific chemical synthesis process critical to its drug.
- Synthon contests validity based on obviousness and patent eligibility.
- The case illustrates complex litigation around chemical process patents.
- A trial is projected for late 2024, with potential to impact market competition.
- Patent enforcement hinges on technical detail and prior art analysis.
FAQs
Q1: What are the main legal defenses used against patent infringement claims?
Infringement defendants commonly rely on patent invalidity arguments based on prior art (Section 103), patent ineligibility under Section 101, or non-infringement due to process differences.
Q2: How does obviousness impact patent validity in chemical processes?
Obviousness considers whether the patented process would have been obvious to a person skilled in the art at the time of invention, based on prior references. If so, the patent can be invalidated.
Q3: What role does prior art play in patent litigation?
Prior art references can challenge both validity and infringement. In validity, prior art aims to show the process was already known or obvious; in infringement, it can establish non-infringement if the accused process differs.
Q4: How does patent law treat process patents versus composition patents?
Process patents protect the methods used to make a compound, while composition patents protect the finished product. Process patents often involve complex, multi-step claims requiring detailed analysis.
Q5: What are the potential consequences of a patent invalidation in this case?
Invalidation could open the market for generic versions, reducing Pfizer’s market share and impacting revenue from the patented drug.
References
[1] United States Patent and Trademark Office. (2020). Patent No. 10,592,107.
[2] Pfizer Inc. v. Synthon Pharmaceuticals, Inc., 1:21-cv-00284, District of Delaware.
[3] Federal Rules of Civil Procedure, Rule 56 (Summary Judgment).
